HYDROPHILIC AND HYDROPHOBIC MATRIX SYSTEM ENGINEERED DEVELOPMENT OF EXTENDED-RELEASE TABLETS OF OXYBUTYNIN CHLORIDE

The present aim study is the formulation development and evaluation of extended-release matrix tablets of oxybutynin chloride by using hydrophilic and hydrophobic matrix systems. The pilot-scale batches of nine formulations were prepared using Eudragit RSPO, Eudragit RLPO, Carbopol 971NF, ethylcellulose individually, and in the combination of above polymer and Avicel PH102 by adopting direct compression method. The fabricated matrix tablets were assessed for their physicochemical properties and in-vitro drug release study. The drug-excipient interaction was evaluated by Fourier transform infrared spectroscopy, where no such interactions were observed. The F1-F3 formulation batches containing Eudragit RSPO in different proportions showed an effective drug release of nearly 99% at 24 h. The F4-F6 formulation batches contained Eudragit RLPO in the diverse amount presented an impressive drug release of >97%. In batches F7-F9, the combination of Eudragit RSPO and Eudragit RLPO produced a remarkable drug release of 100%. The optimized formulation F3 demonstrated a comparative similarity factor ƒ₂ and less difference factor ƒ₁ with that of the marketed tablet. The formulation F3 also passed the essential attributes needed after short-term accelerated stability study.